文献速递炎症性肠病

生物制剂时代克罗恩病术后复发预测模型的开发与外部验证

Development and External Validation of a Predictive Model for Postoperative Recurrence of Crohn's Disease in the Biologic Era.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-03-27

这项前瞻性多中心研究纳入632例接受回结肠切除术的成人克罗恩病患者,旨在识别术后复发危险因素并评估预防性生物制剂疗效。研究发现男性、活动性吸烟、既往手术及生物制剂暴露是内镜复发的危险因素,而预防性生物制剂可显著降低复发风险,基于多因素分析的预测列线图AUC为0.72并在外部队列中表现相似。

要点

  • 男性、吸烟、既往手术及生物制剂暴露增加术后内镜复发风险。
  • 预防性生物制剂使复发风险显著降低(OR 0.31)。
  • 预测列线图AUC 0.72,外部验证表现相似。

核心结论

  • 基于临床因素的模型可估计克罗恩病术后复发风险。
  • 预防性生物制剂在预防早期内镜复发方面高效,且不受风险特征影响。

研究设计与样本

  • 前瞻性多中心研究,纳入632例接受回结肠切除术的成人克罗恩病患者。
  • 主要终点为术后一年内内镜复发(改良Rutgeerts评分≥i2b)。
  • 在2个独立国际队列中进行预测模型的外部验证。

主要发现

  • 632例患者中位病程7.8年,78%既往有生物制剂暴露,44%接受术后生物制剂预防。
  • 237例(37.5%)发生内镜复发。
  • 多变量模型中,男性(OR 1.97;95%CI 1.38-2.83)、活动性吸烟(OR 2.37;95%CI 1.56-3.62)、既往回结肠切除术(OR 1.78;95%CI 1.13-2.82)、既往暴露于1种生物制剂(OR 2.15;95%CI 1.37-3.42)或超过1种生物制剂(OR 2.41;95%CI 1.39-4.22)为危险因素。
  • 生物制剂预防显著降低复发风险(OR 0.31;95%CI 0.20-0.45),且独立于上述危险因素。
  • 预测列线图的受试者工作特征曲线下面积为0.72,外部队列表现相似。

临床怎么用

  • 可利用基于临床因素的列线图评估克罗恩病术后复发风险。
  • 无论风险特征如何,均可考虑使用预防性生物制剂以降低早期内镜复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Ileocolonic resection remains common in Crohn's disease (CD) despite increasing biologic use. The aim of this study was to identify risk factors for postoperative recurrence and to assess prophylactic biologic therapy effectiveness in relation to risk factors. METHODS: This prospective multicentre study included adults with CD undergoing ileocolonic resection (ICR). The primary endpoint was endoscopic recurrence (modified Rutgeerts score ≥i2b) within the year following surgery. Factors associated with endoscopic recurrence were identified using a logistic regression model. A composite time-to-event endpoint was defined for long-term follow-up based on clinical, endoscopic, and/or imaging data. An external validation of our predictive model was performed in 2 independent international cohorts. RESULTS: Among 632 patients (median disease duration, 7.8 years), 78% had prior biologic exposure; 44% received postoperative biologic prophylaxis. Endoscopic recurrence occurred in 237 patients (37.5%). In multivariable model, risk factors included: male sex (odds ratio [OR], 1.97; 95% confidence interval [CI], 1.38-2.83), active smoking (OR, 2.37; 95% CI, 1.56-3.62), previous ICR (OR, 1.78; 95% CI, 1.13-2.82), previous exposure to 1 (OR, 2.15; 95% CI, 1.37-3.42) or more than 1 biologic (OR, 2.41; 95% CI, 1.39-4.22). Biologic prophylaxis significantly reduced recurrence risk (OR, 0.31; 95% CI, 0.20-0.45), independently of these risk factors. A predictive nomogram based on multivariable analysis achieved an area under the receiver operating characteristic curve of 0.72, with similar performance in external cohorts. Clinically significant recurrence, observed in 22.9%, 36.5%, and 53.2% at 3, 5, and 10 years, was associated with severity of early endoscopic recurrence. CONCLUSIONS: Postoperative recurrence risk can be estimated using a model based on clinical factors. Biologic prophylaxis is highly effective in preventing early endoscopic recurrence, regardless of risk profile. CLINICALTRIALS: gov, Number: NCT03458195.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Allez M, Bak MTJ, Brand S, et al. Development and External Validation of a Predictive Model for Postoperative Recurrence of Crohn's Disease in the Biologic Era. Clin Gastroenterol Hepatol. 2026. PMID: 41905522. doi:10.1016/j.cgh.2026.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。